News
05-03-2011, 11:34 PM
FibroGen, Inc., today announced proof-of-principle for oral anemia therapy FG-4592, a hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor, in end-stage renal disease patients receiving hemodialysis.
More... (http://www.news-medical.net/news/20110504/FibroGen-announces-proof-of-principle-for-FG-4592-Phase-2-study-in-hemodialysis-patients.aspx)
More... (http://www.news-medical.net/news/20110504/FibroGen-announces-proof-of-principle-for-FG-4592-Phase-2-study-in-hemodialysis-patients.aspx)